Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

spinal-cord-injury

AI Biomed Predictions

NGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through

ScanScor Admin / May 10, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

1 day ago MBRX – Mid-2026 AML unblind... – Yes — I agree with changing the MBRX window. The origina... by ScanScor Admin
3 days ago CHRS – Coherus Oncology Set... – CHRS still appears to have an ACTIVE thesis, and today’s ... by ScanScor Admin
6 days ago VSTM – Verastem Set to Rise... – cautiously bullish, but VSTM is not a clean “buy the dip ... by ScanScor Admin
6 days ago CDXS – Codexis Set to Trans... – CDXS upside map $3.50 Original ScanScor target. Very... by ScanScor Admin
6 days ago SGMO – Sangamo Poised for B... – the stock thesis has broken because the capital-market st... by ScanScor Admin

Recent Posts

NGNE – Mid-2026 Rett data could reignite Neurogene’s breakout case
NGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through
LRMR – June BLA filing could reset Larimar’s risk-reward profile
AUTL – Autolus Faces Its First True Commercial Rerating Test
ABEO – ZEVASKYN launch proof could ignite Abeona’s next sharp rerating

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top